![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
Aim
To compare oral nifedipine and intravenous labetalol in the treatment of acute severe hypertension in pregnancy (SHP).
Methods
The primary outcomes were the required time to achieve target blood pressure (RTATBP), systolic blood pressure (SBP) and diastolic BP (DBP) after treatment, secondary outcomes were the number of doses (NoD) and adverse events (AEs).
Results
There was no difference between oral nifedipine and intravenous labetalol in SBP, DBP, and AE. However, oral nifedipine provided less RTATBP and NoD.
Conclusion
Oral nifedipine was associated with less RTATBP and NoD and otherwise did not differ from intravenous labetalol.
Disclosure statement
The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.
Author contributions
Minghui Ou and Yan Yu conceived and supervised the study; Yan Yu and Futao Zhang designed experiments; Shichao Cui and Shibo Zhao performed experiments; Minghui Ou and Futao Zhang analyzed data; Minghui Ou Yu and Futao Zhang wrote the manuscript; Yan Yu made the manuscript revisions. All authors reviewed the results and approved the final version of the manuscript.
Data availability statement
No datasets were generated for this study
Contribution to the field statement
These findings showed that nifedipine and labetalol have similar clinical effects, while nifedipine is more efficient than labetalol for treating pregnancy-induced hypertension.
Supplementary Material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/10641955.2023.2209637.